Keyvan Yousefi, MD
Internal Medicine · Beverly Hills, CANPI 1679650386
Payments from drug & device makers
Across 736 payments — averaging $27.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- AbbVie$2K
- UCB, Inc.$2K
- Johnson & Johnson$2K
- GSK$2K
- Invivyd Inc$1K
- plus $6K from 25 others
What the payments were for
- Consulting fees$1,6738%
- Food & beverage$18,12190%
- Education$2591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 190 | $4,403 |
| AbbVie | 103 | $2,435 |
| UCB, Inc. | 68 | $2,078 |
| Johnson & Johnson(2 entities) | 73 | $1,901 |
| GSK | 69 | $1,871 |
| Invivyd Inc | 1 | $1,453 |
| Pfizer | 27 | $754 |
| Lilly USA, LLC | 28 | $716 |
| Radius Health, Inc. | 26 | $693 |
| Novartis | 43 | $673 |
| Mallinckrodt Hospital Products Inc. | 22 | $608 |
| Boehringer Ingelheim | 15 | $483 |
| AstraZeneca(2 entities) | 22 | $464 |
| Cardinal Health 110 LLC | 2 | $200 |
| Aurinia Pharma U.S., Inc. | 7 | $170 |
| E.r. Squibb & Sons, L.L.C. | 8 | $155 |
| Cook Medical LLC | 2 | $126 |
| Scpharmaceuticals Inc. | 1 | $118 |
| Fresenius Kabi USA, LLC | 4 | $117 |
| Sobi, Inc | 3 | $92 |
| Genentech USA, Inc. | 4 | $87 |
| ANI Pharmaceuticals, Inc. | 3 | $86 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $73 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $71 |
| Bioventus LLC | 3 | $69 |
| Zimmer Biomet | 2 | $55 |
| Alvogen Inc | 1 | $26 |
| Sandoz | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Novo Nordisk | 1 | $19 |
| Cumberland Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,053 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 14 | $826,459 |
| SimponiGolimumab | 50 | $304,622 |
| Enbrel SureclickEtanercept | 36 | $288,765 |
| Humira(Cf) PenAdalimumab | 31 | $254,603 |
| SkyriziRisankizumab-Rzaa | 12 | $240,534 |
| Cimzia (2 Pack)Certolizumab Pegol | 34 | $192,907 |
| RinvoqUpadacitinib | 24 | $144,445 |
| EnbrelEtanercept | 19 | $139,183 |
| ProliaDenosumab | 70 | $118,236 |
| ForteoTeriparatide | 15 | $62,837 |
| Xeljanz XrTofacitinib Citrate | 11 | $59,010 |
| Actemra ActpenTocilizumab | 13 | $55,698 |
| ActemraTocilizumab | 11 | $50,705 |
| Diclofenac Sodium | 125 | $12,730 |
| SavellaMilnacipran Hcl | 11 | $10,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa, Enbrel, Prolia | $4,403 | $1,083,878103 claims |
| AbbVieSkyrizi, Rinvoq, Savella | $2,435 | $395,22747 claims |
| Johnson & JohnsonSimponi | $1,901 | $304,62250 claims |
| UCB, Inc.Cimzia (2 Pack) | $2,078 | $192,90734 claims |
| Lilly USA, LLCForteo | $716 | $62,83715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Beverly Hills
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.